Rinvoq Denied by Insurance? How to Appeal

Rinvoq (upadacitinib) is a JAK1-selective inhibitor approved for multiple inflammatory conditions — and denied frequently due to its high cost ($50,000–$70,000/year) and stringent Prior Authorization Denied: How to Appeal" class="auto-link">prior authorization criteria. Here's how to appeal effectively.

Why Insurers Deny Rinvoq

Black box warning concerns. Rinvoq carries an FDA boxed warning (shared with all JAK inhibitors) regarding serious infections, malignancy, thrombosis, and cardiovascular events. Insurers use this warning to justify step therapy requirements, even when a patient's rheumatologist has determined the risk-benefit is appropriate.

Step therapy: biologics first. Plans typically require trial and failure of TNF inhibitors (etanercept, adalimumab/Humira or biosimilar, etc.) before approving Rinvoq.

MACE risk concerns. Following the ORAL Surveillance trial, FDA added a class warning for JAK inhibitors regarding major adverse cardiovascular events. Plans may require cardiovascular risk documentation.

Indication mismatch. Rinvoq has multiple FDA indications; the PA criteria differ by indication.

Rinvoq FDA-Approved Indications

• Rheumatoid arthritis (RA): Moderate-to-severe RA in adults with inadequate response or intolerance to methotrexate. Can be used as monotherapy or with methotrexate
• Psoriatic arthritis (PsA): Active PsA in adults with inadequate response to biologic DMARDs
• Ankylosing spondylitis (AS) / Axial spondyloarthritis (axSpA): Active ankylosing spondylitis; also non-radiographic axSpA
• Atopic dermatitis: Moderate-to-severe AD in adults and adolescents 12+ not controlled with other therapies
• Crohn's disease: Moderately to severely active Crohn's disease in adults
• Ulcerative colitis: Moderately to severely active UC in adults

Building Your Appeal

Document TNF Inhibitor History

For most indications, you need to show prior biologic DMARD trial and failure or intolerance. Document:

• Which TNF inhibitor(s) were tried (adalimumab/biosimilar, etanercept, infliximab/biosimilar, etc.)
• Dates and duration of therapy
• Reason for failure: inadequate response (with objective measures), adverse effects, or contraindication
• Laboratory data showing active disease despite treatment (elevated CRP, ESR, DAS28, CDAI)

Cite Objective Disease Activity Measures

For RA: DAS28-CRP ≥3.2 (moderate disease) or ≥5.1 (high disease activity); CDAI ≥10; SDAI ≥11 For AS: BASDAI ≥4; ASDAS-CRP ≥2.1 For AD: IGA ≥3; EASI ≥16; SCORAD ≥25 For Crohn's: CDAI ≥220; or SES-CD showing active disease

Reference Clinical Guidelines

ACR (American College of Rheumatology) Guidelines 2021: Recommend JAK inhibitors including upadacitinib for patients with inadequate response to conventional DMARDs or biologics. For patients with no prior biologic use and moderate-to-high disease activity despite MTX, both biologics and JAK inhibitors are acceptable options.

AAD (American Academy of Dermatology): Systemic JAK inhibitors recommended for moderate-to-severe atopic dermatitis not controlled with topical therapies. Upadacitinib showed superior efficacy over dupilumab in head-to-head trial (Heads Up trial).

AGA (American Gastroenterological Association): Rinvoq recommended for patients with Crohn's disease with inadequate response to anti-TNF agents.

Address the Boxed Warning Proactively

Your rheumatologist should explicitly state:

• Patient's cardiovascular risk profile (ASCVD 10-year risk)
• Absence of active malignancy
• Prior vaccinations (herpes zoster vaccine recommended before starting JAK inhibitors)
• Informed consent discussion
• Monitoring plan for infections, CBC, LFTs, lipids

If the patient is low cardiovascular risk and younger, explicitly note that ACR guidelines support JAK inhibitor use in this population.

Request Peer-to-Peer Review

Insurer medical reviewers are often internists or general practitioners reviewing complex inflammatory disease. A rheumatologist-to-rheumatologist (or rheumatologist-to-medical director) peer-to-peer significantly improves overturn rates.

Step-by-Step Appeal Process

1. Request the denial letter with specific PA criteria cited
2. Have your physician write a comprehensive letter with disease severity scores, prior therapy failures, guideline citations
3. Request peer-to-peer review within 72 hours of denial
4. File formal internal appeal if peer-to-peer fails
5. Request external independent review if internal appeal denied
6. Consider requesting an expedited appeal if disease progression poses urgent clinical harm

Sample Appeal Language

"I am appealing the denial of Rinvoq (upadacitinib) [dose] [frequency] for [indication]. My rheumatologist, Dr. [Name], has determined that Rinvoq is medically necessary based on documented disease activity ([DAS28/BASDAI/EASI score]) despite adequate trial and failure of [prior therapies: list with dates].

Per ACR 2021 Treatment Guidelines for [RA/AS/PsA], upadacitinib is an appropriate treatment for patients with inadequate response to prior DMARD or biologic therapy. The patient's cardiovascular risk profile has been assessed as [low/moderate] and is appropriate for JAK inhibitor therapy. I respectfully request reversal of this denial."

Patient Assistance

• AbbVie myAbbVie Assist: Patient assistance for commercially insured and uninsured patients
• Rinvoq copay program: Eligible patients may pay $0/month copay

Fight Back With ClaimBack

ClaimBack generates Rinvoq-specific appeal letters citing ACR/AAD/AGA guidelines, your prior therapy history, and the appropriate clinical criteria for your specific indication.

Free analysis. Appeal letter from USD 12.

Related Reading

• Prior Authorization Denied? How to Appeal
• What Is Medical Necessity and How to Prove It
• How to Write an Insurance Appeal Letter That Works